Dianthus Therapeutics unveils new bifunctional fusion protein DNTH312
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St ends mixed as oil takes a pause
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases
August 4, 2026 7:00 AM EDTDNTH312 is an internally developed bifunctional fusion protein targeting potent inhibition of active C1s (aC1s) and BAFF/APRIL, two validated pathways with complementary disease modifying mechanisms
DNTH312 demonstrated comparable in vitro potency and aC1s inhibition to claseprubart, with a comparable non-human primate (NHP) half-life
DNTH312 showed similar depth of Ig reductions vs. povetacicept following a single dose in NHPs
By building on claseprubarts best-in-class profile, DNTH312 strengthens Dianthus leadership in neuromuscular disease, while expanding into additional autoimmune diseases where both B cell... More
